Representatives of the Cimathe Clinica Universidad de Navarrathe Navarra Hospital Complexthe Michael Servetus Foundation through Navarrabiomed and the business biotechnology Recombina Biotech have met to hold a scientific meeting to assess the progress and implementation of project in its first year.

The representatives of each institution have presented the work developed during this time, both in their centers and collaboratively. Specifically, they have actively collaborated in the search and selection of possible new targets to treat different types of solid and hematological tumors with CAR-T therapies. At the same time, already identified targets have been validated and progress has been made in their application for the development of CAR-T optimized for clinical application. Also, the data obtained in the construction and characterization of new CARs has been shown. Promising alternatives have emerged in the development of project that will be evaluated for their transfer to the clinical internship . Likewise, the knowledge of the immune T cells and in contrasting strategies to improve their antitumor activity have been studied in depth.

After the celebration of this scientific meeting , the members of the Navarra consortium have agreed on the opportunity that the project DESCARTHeS is providing to increase the synergy between the participants in each package of work. Their goal for the coming months is to continue with the established schedule and to take full advantage of all the scientific and technological resources of all the partners to facilitate the implementation of CAR-T therapy in Navarra.